The trajectory of companies tied to Sildenafil's history presents a intricate investment scenario . While the initial boom generated substantial returns , generic copies have significantly diminished market share . Investing in connected pharmaceutical companies now requires a thorough assessment of proprietary safeguards, evolving patient trends ,